Volume : 13, Issue : 06, June – 2026

Title:

FORMULATION DEVELOPMENT AND EVALUATION OF THERMOREVERSIBLE OCULAR IN SITU HYDROGEL OF OLOPATADINE HYDROCHLORIDE FOR SUSTAINED OPHTHALMIC DRUG DELIVERY

Authors :

Sana Dildar Mujawar*, Dr. Narhari Amol Yedake, Dr. Ravi Uttamrao Kurhade, Mr. Nishinandan Manikrao Shinde

Abstract :

The present study aimed to develop and evaluate a thermoreversible ocular in situ hydrogel of Olopatadine Hydrochloride for sustained ophthalmic drug delivery. The formulation was designed to overcome the limitations of conventional eye drops, including poor ocular bioavailability, rapid precorneal elimination, and frequent dosing requirements. Preformulation studies confirmed the purity and compatibility of the drug with selected excipients. Thermoreversible in situ hydrogels were prepared using Poloxamer 407, Poloxamer 188, HPMC K4M, and Carbopol 940 by the cold method. The prepared formulations were evaluated for physicochemical parameters such as appearance, pH, drug content, viscosity, gelling capacity, isotonicity, sterility, and in vitro drug release. All formulations exhibited acceptable characteristics for ophthalmic application. Among them, formulation F9 demonstrated optimal performance with suitable pH, satisfactory drug content, rapid gelation, appropriate viscosity, and prolonged drug release. The optimized formulation showed sustained release behavior and followed the Korsmeyer–Peppas kinetic model with a non-Fickian diffusion mechanism. Stability studies indicated good formulation stability under accelerated storage conditions. The developed thermoreversible ocular in situ hydrogel of Olopatadine Hydrochloride offers a promising approach for sustained ophthalmic drug delivery by enhancing ocular residence time, improving bioavailability, reducing dosing frequency, and increasing patient compliance.
KEYWORDS: Olopatadine Hydrochloride, Thermoreversible Hydrogel, Ocular In Situ Gel, Sustained Drug Delivery, Ophthalmic Formulation, Ocular Bioavailability.

Cite This Article:

Please cite this article in press Sana Dildar Mujawar et al., Formulation Development And Evaluation Of Thermoreversible Ocular In Situ Hydrogel Of Olopatadine Hydrochloride For Sustained Ophthalmic Drug Delivery, Indo Am. J. P. Sci, 2026; 13(06).

REFERENCES:

1. Shaikh S, Momin A. Formulation and evaluation of ion-triggered ocular in situ gel containing ciprofloxacin hydrochloride and olopatadine hydrochloride. Asian J Pharm Clin Res. 2024;17(1):145-152.
2. Afreen S, Begum N, Fatima R, Khan T. Development and evaluation of pH-responsive ophthalmic in situ gel of ciprofloxacin hydrochloride and olopatadine hydrochloride. Int J Pharm Investig. 2023;13(4):521-529.
3. Bowya PV, Reddy MS, Kumar PS. Formulation and evaluation of ophthalmic in situ gel containing prednisolone and moxifloxacin by pH-triggered method. World J Pharm Pharm Sci. 2023;12(6):1185-1196.
4. Patel DJ, Patel KR, Shah DP. Formulation and evaluation of ophthalmic in situ gel of natamycin. Int J Pharm Sci Rev Res. 2022;73(1):45-53.
5. Vyas U, Sharma P, Mehta D. Preparation and evaluation of ophthalmic in situ gelling system of norfloxacin for conjunctivitis treatment. Indo Am J Pharm Sci. 2022;9(5):210-219.
6. Musarurwa HT, Tavengwa NT. Stimuli-responsive polymers in advanced drug delivery systems: applications in ocular therapeutics. Pharmaceutics. 2022;14(8):1624-1641.
7. Pandey P, Gupta R, Kumar S. Stimuli-responsive in situ gel systems for sustained ocular drug delivery: recent perspectives. Drug Deliv Transl Res. 2021;11(5):1864-1881.
8. Cassano R, Trombino S, Ferrarelli T, Picci N. Gel-based materials in ophthalmic drug delivery systems. Gels. 2021;7(4):203-221.
9. Shaikh S, Khan M, Patel R. Preparation and evaluation of pH-triggered ophthalmic in situ gel of loteprednol etabonate. Int J Res Pharm Sci. 2021;12(2):1310-1318.
10. Al Juboori ZA, Mohammed AA, Hasan SA. Formulation and evaluation of ocular in situ gel containing ciprofloxacin and naproxen. Iraqi J Pharm Sci. 2021;30(2):56-65.
11. Gupta NB, Singh A, Sharma V. Formulation and evaluation of ion-sensitive ophthalmic in situ gel of moxifloxacin hydrochloride. Int J Appl Pharm. 2021;13(6):142-150.
12. Baral KC, Das S, Mishra B. Formulation and evaluation of ophthalmic in situ gel of ciprofloxacin hydrochloride using pH-sensitive polymers. Int J Pharm Sci Nanotechnol. 2020;13(3):4851-4860.
13. Bharath S, Kumar PS, Reddy YS. Development and evaluation of pH-triggered ophthalmic in situ gel of brimonidine tartrate. Int J Pharm Pharm Sci. 2020;12(8):74-82.
14. Vigani B, Rossi S, Sandri G, Ferrari F, Bonferoni MC, Caramella C. Recent advances in in situ gelling systems for ocular drug delivery. Eur J Pharm Biopharm. 2020;148:1-14.
15. Jumelle C, Gholizadeh S, Annabi N, Dana R. Advances and limitations of drug delivery systems formulated as eye drops. J Control Release. 2020;321:1-22.
16. Chaudhari SP, Desai PP. Formulation and evaluation of niosomal in situ gel for ocular drug delivery. Int J Pharm Sci Drug Res. 2019;11(4):160-168.
17. Ranch KM, Maulvi FA, Naik MJ, Shah DO. Optimization of ophthalmic in situ gel using design of experiments for sustained ocular delivery. Drug Dev Ind Pharm. 2019;45(3):466-476.
18. Al-Kinani AA, Zidan G, Elsaid N, Seyfoddin A, Alani AWG. Ophthalmic gels: past, present and future perspectives. Acta Biomater. 2018;79:14-36.
19. Ranch K, Maulvi F, Shah D. Development and evaluation of sustained release ophthalmic in situ gel of dexamethasone sodium phosphate and chloramphenicol. J Drug Deliv Sci Technol. 2017;39:175-184.
20. Aligeti SK, Ch RS, Rao YM. Formulation and evaluation of ocular in situ gel of flurbiprofen by pH-triggered system. Int J Pharm Sci Rev Res. 2017;42(1):95-102.
21. Makwana SB, Patel VA, Parmar SJ. Formulation and evaluation of pH-responsive ophthalmic in situ gel of ciprofloxacin hydrochloride. Int J Pharm Investig. 2016;6(4):207-213.
22. Mandal S, Thimmasetty J, Prabhushankar GL, Geetha MS. Formulation and evaluation of an in situ gel-forming ophthalmic drug delivery system of moxifloxacin hydrochloride. Int J Pharm Investig. 2016;6(3):157-165.
23. Huang D, Chen YS, Rupenthal ID. Overcoming ocular drug delivery barriers through the use of thermosensitive in situ hydrogels. Drug Discov Today. 2016;21(6):1030-1036.
24. Kesarla R, Tank T, Vora PA, Shah T, Parmar S. Preparation and evaluation of nanoparticle-loaded ophthalmic in situ gels for enhanced ocular delivery. AAPS PharmSciTech. 2016;17(5):1159-1172.
25. Kumar S, Himmelstein KJ, Kadam RS. Development of temperature-sensitive in situ gelling system for ocular delivery of ofloxacin. Acta Pharm Sin B. 2013;3(2):72-81.
26. Varshosaz J, Tabbakhian M, Salmani Z. Designing of a thermosensitive chitosan-poloxamer in situ gel for ocular delivery of ciprofloxacin. Open Drug Deliv J. 2008;2:61-70.
27. Cao Y, Zhang C, Shen W, Cheng Z, Yu LL, Ping Q. Poly(N-isopropylacrylamide)-chitosan thermosensitive in situ gel for ocular drug delivery. J Control Release. 2007;120(3):186-194.
28. Qi H, Chen W, Huang C, Li L, Chen C, Li W, et al. Development of a poloxamer/carbopol in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm. 2007;337(1-2):178-187.
29. Sweetman SC. Martindale: The Complete Drug Reference. 38th ed. London: Pharmaceutical Press; 2014.
30. Rasve VR, Chakraborty A. A comprehensive review on self-micro emulsifying drug delivery systems (SMEDDS). Int J Pharm Pharm Res. 2022;26(1):206-224.
31. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. New Delhi: Jaypee Brothers Medical Publishers; 2019.
32. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw Hill Education; 2018.
33. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Vol II. Ghaziabad: IPC; 2022.
34. United States Pharmacopoeial Convention. United States Pharmacopoeia and National Formulary (USP-NF). Rockville: USP Convention; 2023.
35. DrugBank Online. Olopatadine Hydrochloride. Available from: https://go.drugbank.com/
36. National Center for Biotechnology Information. PubChem Compound Summary for Olopatadine Hydrochloride. Bethesda (MD): National Library of Medicine; 2024.
37. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012.
38. Schmolka IR. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J Biomed Mater Res. 1972;6(6):571-582.
39. Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23(12):2709-2728.
40. Alexandridis P, Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces. Colloids Surf A Physicochem Eng Asp. 1995;96(1-2):1-46.
41. Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Technol Prod Manuf. 1984;5(3):1-9.
42. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012.
43. Thakur RR, McMillan HL, Jones DS. Solvent induced phase transition-based in situ forming controlled release drug delivery implants. J Control Release. 2014;176:8-23.
44. Lubrizol Advanced Materials Inc. Carbopol® Polymer Technical Data Sheet. Cleveland, Ohio; 2018.
45. Rasve V, Chakraborty AK, Jain SK, Vengurlekar S. Comparative evaluation of antidiabetic activity of ethanolic leaves extract of Clematis triloba and their SMEDDS formulation in streptozotocin-induced diabetic rats. J Popul Ther Clin Pharmacol. 2022;29(4):959-971. doi:10.53555/jptcp.v29i04.2360.
46. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. 7th ed. London: Pharmaceutical Press; 2012.
47. Bonacucina G, Cespi M, Palmieri GF. Characterization and stability of emulsion gels based on acrylamide/sodium acryloyldimethyl taurate copolymer. AAPS PharmSciTech. 2009;10(2):368-375.
48. Tamburic S, Craig DQM. Rheological evaluation of polyacrylic acid hydrogels. Pharm Sci. 1995;1(3):107-109.
49. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VHA, de Freitas O, Lopez RFV. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm. 2010;75(2):186-193.
50. Kaur IP, Kanwar M. Ocular preparations: the formulation approach. Drug Dev Ind Pharm. 2002;28(5):473-493.
51. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev. 2005;57(11):1595-1639.
52. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol. 2013;2(2):47-64.
53. Remington JP. Remington: The Science and Practice of Pharmacy. 22nd ed. Philadelphia: Pharmaceutical Press; 2013.
54. Bhardwaj TR, et al, A Natural gum and modified natural gums as sustained release carriers, Drug Devel Ind Pharm, 26, 2000, 1025-1038.
55. Nirmal HB, et al, In-situ Gel: New trend in controlled and sustained drug delivery system, Int J Pharma-tech Res, 2, 2010, 1398-1408.
56. Geethalakshmi A, et al, sustained ocular delivery of brimonidine tartrate using ion activated in situ gelling system, Current Drug Delivery, 9, 2012, 197-204.
57. Balasubramaniam J, et al, In vitro and in vivo evaluation of the Gel-rite gellan gum-based ocular delivery system for indomethacin, Acta Pharm, 53, 2003, 251-61.